Why Neurocrine Biosciences Stock Is on Investor Radar Today

Neurocrine Biosciences (NBIX) is drawing fresh attention after a recent move in its share price. The stock last closed at US$162.71, prompting investors to reassess its current valuation and growth profile.

Recent gains have come in bursts, with a 1-day share price return of 1.15% and a 90-day share price return of 25.37%, while the 1-year total shareholder return of 30.16% points to momentum that has been building over a longer horizon.

If you are watching how healthcare and biotech trends are playing out in the market, this could be a good moment to scan a curated list of 40 healthcare AI stocks

With Neurocrine Biosciences reporting US$3.1b in revenue and US$668.6m in net income, and the stock trading at US$162.71 with an indicated intrinsic discount, is this a genuine entry point or is the market already pricing in future growth?

Most Popular Narrative: 15.6% Undervalued

At a last close of $162.71 against a narrative fair value of $192.88, the current share price sits well below what this widely followed model suggests, putting the focus firmly on how Neurocrine Biosciences executes its growth plans.

A broad, late-stage and diversified CNS pipeline, including multiple Phase III programs targeting major depressive disorder and schizophrenia, leverages advances in precision medicine and increases visibility for future earnings, supporting potential future valuation multiple expansion.

Want to see what is baked into that upside gap? The narrative leans heavily on higher revenue, wider margins and a future earnings multiple that has to hold up. The exact mix of those three levers might surprise you.

Result: Fair Value of $192.88 (UNDERVALUED)

However, the story can change quickly if pricing pressure on INGREZZA persists or if uptake of newer products like CRENESSITY falls short of current analyst assumptions.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

Given the mix of optimism and caution in this story, it makes sense to check the numbers yourself and decide where you stand. To see what investors are currently excited about, review the 3 key rewards

Looking for more investment ideas?

If you only focus on one stock, you could miss other compelling setups. Use the Simply Wall Street screener to uncover fresh ideas that fit your style.

• Target stability by checking out companies in the 67 resilient stocks with low risk scores that may suit a more cautious approach.
• Hunt for value by scanning the 46 high quality undervalued stocks where quality businesses might be trading at appealing prices.
• Spot resilience by reviewing the solid balance sheet and fundamentals stocks screener (47 results) that highlight firms with stronger financial footing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.